Improving Treatment for Disorders of the Nervous System

Developing Therapeutic Proteins for Neuropathic Pain and Hearing Loss

Our Company

Hoba Therapeutics was established in 2017 with seed funding from Novo Holdings and Borean Innovation.

Our focus is to develop novel biopharmaceuticals and improve the treatment of chronic neurological disorders

Neuropathic Pain and Hearing Loss


HB-086 and HB-097 are recombinant drug candidates of human Meteorin and human Cometin (meteorin-like protein). This family of proteins have unique therapeutic properties and act on sensory nerve cells and their supporting glia cells.

Our Pipeline

HB-086 is in late preclinical develop-ment and is expected to enter clinical development in 3rd quarter of 2022. Target indications are CIPN and trigeminal neuralgia.

HB-097 is in development for sensorineural hearing loss. Clinical phase 1 is planned for 1st half of 2023

Latest News

14 October 2021

Hoba Therapeutics has been selected by The European Commission’s European Innovation Council (EIC) as a start-up champion. Hoba will receive grant funding and qualifies for further equity investment from EIC Accelerator.

August 2019 - New Publication

Antihyperalgesic effects of Meteorin in the rat chronic constriction injury model: a replication study.

October 2018 - Grand Solution Funding  (IFD)

Danish Hoba Therapeutics and a consortium of national and international partners have secured the ongoing development of the drug candidate HB-086 for treatment of neuropathic pain with an investment from Innovation Fund Denmark (IFD) of DKK18.4M (≈€2.5M), and thereby a major step towards clinical trials